open access

Vol 59, No 5 (2008)
Postgraduate education
Published online: 2008-09-26
Submitted: 2013-02-15
Get Citation

Medullary thyroid cancer - the present state of art

Robert Krysiak, Bogdan Marek, Bogusław Okopień
Endokrynologia Polska 2008;59(5):446-455.

open access

Vol 59, No 5 (2008)
Postgraduate education
Published online: 2008-09-26
Submitted: 2013-02-15

Abstract

Medullary thyroid cancer is a neuroendocrine tumour originating from the parafollicular C cells of the thyroid gland that accounts for about 5-10% of all thyroid carcinomas. It may occur either sporadically (75%) or in familial forms (25%) in familial medullary thyroid carcinoma and multiple endocrine neoplasia types 2A and 2B. Distinct clinical phenotypes in hereditary medullary thyroid cancer result from different missense germline mutations in the RET protooncogene. Medullary thyroid cancer produce calcitonin, measurement of which indicates the presence of tumour in at-risk individuals and the effectiveness of management in treated patients. Prognosis of patients with medullary thyroid cancer is variable, but the more constant factors that affect it are the stage of disease and the age of the patient. The goal of treatment of patients suffering from medullary thyroid cancer is to detect and surgically remove disease at its early stage. Total thyroidectomy with local nodal dissection leads to achievement of biochemical cure in more than 80% of cases. The tumour does not take up radioactive iodine, is relatively radioresistant, and there is no known effective systemic therapy for this cancer. The purpose of this article is to summarise the present state of knowledge on the etiology, clinical presentation, management, prognosis, and genetics of medullary thyroid cancer. (Pol J Endocrinol 2008; 59 (5): 446-455)

Abstract

Medullary thyroid cancer is a neuroendocrine tumour originating from the parafollicular C cells of the thyroid gland that accounts for about 5-10% of all thyroid carcinomas. It may occur either sporadically (75%) or in familial forms (25%) in familial medullary thyroid carcinoma and multiple endocrine neoplasia types 2A and 2B. Distinct clinical phenotypes in hereditary medullary thyroid cancer result from different missense germline mutations in the RET protooncogene. Medullary thyroid cancer produce calcitonin, measurement of which indicates the presence of tumour in at-risk individuals and the effectiveness of management in treated patients. Prognosis of patients with medullary thyroid cancer is variable, but the more constant factors that affect it are the stage of disease and the age of the patient. The goal of treatment of patients suffering from medullary thyroid cancer is to detect and surgically remove disease at its early stage. Total thyroidectomy with local nodal dissection leads to achievement of biochemical cure in more than 80% of cases. The tumour does not take up radioactive iodine, is relatively radioresistant, and there is no known effective systemic therapy for this cancer. The purpose of this article is to summarise the present state of knowledge on the etiology, clinical presentation, management, prognosis, and genetics of medullary thyroid cancer. (Pol J Endocrinol 2008; 59 (5): 446-455)
Get Citation

Keywords

medullary thyroid cancer; etiopathogenesis; diagnosis; treatment; multiple endocrine neoplasia type 2 (MEN-2)

About this article
Title

Medullary thyroid cancer - the present state of art

Journal

Endokrynologia Polska

Issue

Vol 59, No 5 (2008)

Pages

446-455

Published online

2008-09-26

Bibliographic record

Endokrynologia Polska 2008;59(5):446-455.

Keywords

medullary thyroid cancer
etiopathogenesis
diagnosis
treatment
multiple endocrine neoplasia type 2 (MEN-2)

Authors

Robert Krysiak
Bogdan Marek
Bogusław Okopień

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl